Company / Cost of Revenue
Aquestive Therapeutics, Inc. Cost of Revenue History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$18.6M
FY2025
5-year range
$17.9M / $20.8M
FY2021-FY2025
Trend
+3.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has fluctuated over the past 5 years, ranging from $18M in FY2024 to $21M in FY2023.
Based on SEC 10-K filings.
$19M in FY2025 with a 5-year CAGR of -1.8%.
Improved from $21M to $19M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -1.4%
- 5-Year CAGR
- -1.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -1.8%, indicating a declining trend.
- In FY2025, cost of revenue increased 3.8% year-over-year.
- Peak cost of revenue was recorded in FY2023.
- Lowest cost of revenue in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.6M | +3.8% |
| FY2024 | $17.9M | -14.2% |
| FY2023 | $20.8M | +7.5% |
| FY2022 | $19.4M | - |
| FY2021 | - | - |
| FY2020 | $20.4M | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026